Author: michael987

Vascular disrupting agents (VDAs) are the novel oncology drugs being developed to more specifically combat complex, life threatening cancer indications London Roots Analysis has announced the addition of “Vascular Disrupting Agents Market,... Read More

Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments in this industry Roots Analysis has announced... Read More

The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely... Read More

Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and... Read More

Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players... Read More

The recent approval of Aduhelm™, an amyloid beta-directed antibody has led to players seeking approval for similar therapies; various interventions are being evaluated for the treatment / management of the... Read More